Edesa Biotech Files 8-K on Financials
Ticker: EDSA · Form: 8-K · Filed: Dec 12, 2025 · CIK: 1540159
| Field | Detail |
|---|---|
| Company | Edesa Biotech, Inc. (EDSA) |
| Form Type | 8-K |
| Filed Date | Dec 12, 2025 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: financial-reporting, corporate-actions
Related Tickers: EDSA
TL;DR
EDSA filed an 8-K on 12/12/25 covering financials. Formerly Stellar Biotech.
AI Summary
Edesa Biotech, Inc. filed an 8-K on December 12, 2025, reporting on its results of operations and financial condition. The filing also includes financial statements and exhibits. The company was formerly known as Stellar Biotechnologies, Inc., with a name change effective January 20, 2012.
Why It Matters
This filing provides investors with an update on Edesa Biotech's financial performance and operational status, which is crucial for evaluating the company's health and future prospects.
Risk Assessment
Risk Level: low — This is a routine 8-K filing for financial reporting and does not indicate any unusual or significant events.
Key Players & Entities
- Edesa Biotech, Inc. (company) — Registrant
- Stellar Biotechnologies, Inc. (company) — Former company name
- December 12, 2025 (date) — Date of report
- January 20, 2012 (date) — Date of name change
FAQ
What is the primary purpose of this 8-K filing?
The primary purpose of this 8-K filing is to report on Edesa Biotech, Inc.'s Results of Operations and Financial Condition, and to include Financial Statements and Exhibits.
When was this 8-K report filed?
This 8-K report was filed as of December 12, 2025.
What was Edesa Biotech, Inc.'s former name?
Edesa Biotech, Inc.'s former name was Stellar Biotechnologies, Inc.
On what date was the company's name changed from Stellar Biotechnologies, Inc.?
The company's name was changed from Stellar Biotechnologies, Inc. on January 20, 2012.
Where is Edesa Biotech, Inc.'s principal executive office located?
Edesa Biotech, Inc.'s principal executive office is located at 100 Spy Court, Markham, Ontario, L3R 5H6.
Filing Stats: 507 words · 2 min read · ~2 pages · Grade level 10 · Accepted 2025-12-12 16:25:30
Filing Documents
- f8k_121125.htm (8-K) — 15KB
- exh_991.htm (EX-99.1) — 61KB
- 0001171843-25-007913.txt ( ) — 275KB
- gnw-20250101.xsd (EX-101.SCH) — 3KB
- gnw-20250101_def.xml (EX-101.DEF) — 25KB
- gnw-20250101_lab.xml (EX-101.LAB) — 35KB
- gnw-20250101_pre.xml (EX-101.PRE) — 24KB
- f8k_121125_htm.xml (XML) — 3KB
02. Results of Operations and Financial Condition
Item 2.02. Results of Operations and Financial Condition. On December 12, 2025, Edesa Biotech, Inc. (the "Company") issued a press release announcing its financial results for the fiscal year ended September 30, 2025 (the "Earnings Release"). The full text of the Earnings Release is attached hereto as Exhibit 99.1. The information furnished herein and therein shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act") or otherwise subject to the liabilities of that Section, or incorporated by reference in any filing under the Exchange Act or the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such a filing.
01. Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Press release issued by Edesa Biotech, Inc. dated December 12, 2025. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document). SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. EDESA BIOTECH, INC. Date: December 12, 2025 By: /s/ Peter J. Weiler Peter J. Weiler Chief Financial Officer